HeXun Biosciences Co (ROCO:6986) Piotroski F-Score: 6 (As of Jul. 12, 2026) — 14% Below Median


ROCO:6986 HeXun Biosciences Co Ltd ROCO:6986
23 GF Score
Price NT$47.00
! 1 Warning Sign
View Full Analysis

What is HeXun Biosciences Co Piotroski F-Score?

HeXun Biosciences Co ROCO:6986 23 Piotroski F-Score is 6 as of Jul. 12, 2026, which is 14% below its 10-year median of 7.00. GuruFocus rates ROCO:6986 with a GF Score™ of 23/100. The stock has 1 warning sign investors should review. Among 1,333 Biotechnology companies, HeXun Biosciences Co ranks better than 91.97% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

HeXun Biosciences Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for HeXun Biosciences Co's Piotroski F-Score or its related term are showing as below:

ROCO:6986' s Piotroski F-Score Range Over the Past 10 Years
Min: 6   Med: 7   Max: 7
Current: 6

During the past 6 years, the highest Piotroski F-Score of HeXun Biosciences Co was 7. The lowest was 6. And the median was 7.

HeXun Biosciences Co  (ROCO:6986) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


HeXun Biosciences Co Piotroski F-Score Related Terms


HeXun Biosciences Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for HeXun Biosciences Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HeXun Biosciences Co Piotroski F-Score Chart

HeXun Biosciences Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial N/A 7.00 7.00 6.00 6.00

HeXun Biosciences Co Quarterly Data
Dec20 Dec21 Dec22 Jun23 Dec23 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 6.00 0.00 0.00 6.00

ROCO:6986 vs VRTX, REGN, ALNY: Piotroski F-Score Comparison

For the Biotechnology subindustry, HeXun Biosciences Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HeXun Biosciences Co Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HeXun Biosciences Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where HeXun Biosciences Co's Piotroski F-Score falls into.


ROCO:6986
23GF Score
HeXun Biosciences Co Ltd ROCO:6986
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Net Income was NT$111.9 Mil.
Cash Flow from Operations was NT$163.9 Mil.
Revenue was NT$293.2 Mil.
Gross Profit was NT$266.3 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was (706.919 + 837.065) / 2 = NT$771.992 Mil.
Total Assets at the begining of this year (Dec24) was NT$706.9 Mil.
Long-Term Debt & Capital Lease Obligation was NT$32.6 Mil.
Total Current Assets was NT$609.6 Mil.
Total Current Liabilities was NT$62.5 Mil.
Net Income was NT$147.2 Mil.

Revenue was NT$286.4 Mil.
Gross Profit was NT$260.7 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was (571.429 + 706.919) / 2 = NT$639.174 Mil.
Total Assets at the begining of last year (Dec23) was NT$571.4 Mil.
Long-Term Debt & Capital Lease Obligation was NT$32.0 Mil.
Total Current Assets was NT$483.2 Mil.
Total Current Liabilities was NT$53.8 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

HeXun Biosciences Co's current Net Income (TTM) was 111.9. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

HeXun Biosciences Co's current Cash Flow from Operations (TTM) was 163.9. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=111.906/706.919
=0.15830102

ROA (Last Year)=Net Income/Total Assets (Dec23)
=147.223/571.429
=0.25764006

HeXun Biosciences Co's return on assets of this year was 0.15830102. HeXun Biosciences Co's return on assets of last year was 0.25764006. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

HeXun Biosciences Co's current Net Income (TTM) was 111.9. HeXun Biosciences Co's current Cash Flow from Operations (TTM) was 163.9. ==> 163.9 > 111.9 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Dec25
=32.622/771.992
=0.04225691

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=31.984/639.174
=0.05003958

HeXun Biosciences Co's gearing of this year was 0.04225691. HeXun Biosciences Co's gearing of last year was 0.05003958. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec25)=Total Current Assets/Total Current Liabilities
=609.605/62.544
=9.74681824

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=483.246/53.755
=8.989787

HeXun Biosciences Co's current ratio of this year was 9.74681824. HeXun Biosciences Co's current ratio of last year was 8.989787. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

HeXun Biosciences Co's number of shares in issue this year was 46.021. HeXun Biosciences Co's number of shares in issue last year was 46.035. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=266.275/293.225
=0.90809106

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=260.671/286.418
=0.91010691

HeXun Biosciences Co's gross margin of this year was 0.90809106. HeXun Biosciences Co's gross margin of last year was 0.91010691. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=293.225/706.919
=0.41479293

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=286.418/571.429
=0.50123112

HeXun Biosciences Co's asset turnover of this year was 0.41479293. HeXun Biosciences Co's asset turnover of last year was 0.50123112. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+1+1+0+0
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

HeXun Biosciences Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 6 mean?
HeXun Biosciences Co (ROCO:6986) has a Piotroski F-Score of 6 as of Jul. 12, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on HeXun Biosciences Co and its competitors. This is 14% below median its historical median of 7.00. Over the past decade, HeXun Biosciences Co's Piotroski F-Score has ranged from 6.00 to 7.00. According to the industry distribution chart, HeXun Biosciences Co ranks #107 out of 1333 companies in the Biotechnology industry, placing it in the top 8%.
Is HeXun Biosciences Co's Piotroski F-Score too high?
HeXun Biosciences Co's current Piotroski F-Score of 6 is 14% below median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 6.00 to a high of 7.00. The Biotechnology industry median Piotroski F-Score is 3.00. HeXun Biosciences Co's value of 6 is 100% above this industry median. Based on the distribution chart, HeXun Biosciences Co ranks #107 out of 1333 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, HeXun Biosciences Co has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does HeXun Biosciences Co's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HeXun Biosciences Co ranks #107 out of 1333 companies for Piotroski F-Score. This places HeXun Biosciences Co in the top 8% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 3.00. HeXun Biosciences Co's value of 6 is 100% above this benchmark. Historically, HeXun Biosciences Co's own Piotroski F-Score has ranged from 6.00 to 7.00 over the past decade. While the company's 10-year median is 7.00 vs. the industry median of 3.00, HeXun Biosciences Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,333 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HeXun Biosciences Co's current Piotroski F-Score of 6 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on HeXun Biosciences Co and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HeXun Biosciences Co's current Piotroski F-Score is 6, which is 14% below median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeXun Biosciences Co stock overvalued right now?
HeXun Biosciences Co (ROCO:6986) has a current Piotroski F-Score of 6. The current Piotroski F-Score is 6, which is 14% below median its 10-year median of 7.00 and 100% above the Biotechnology industry median of 3.00. HeXun Biosciences Co's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For HeXun Biosciences Co (ROCO:6986), the current Piotroski F-Score is 6 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HeXun Biosciences Co Business Description

Address Chunri Road, 6 F., No. 1490, Taoyuan District, Taoyuan, TWN
HeXun Biosciences Co Ltd is engaged in the research and development of cell drugs and cell derivatives. It conducts research and development jointly with medical research institutions to use stem cells to treat cardiovascular, immune-inflammatory, and neurodegenerative diseases to develop innovative cell drugs and treatment methods. The company's main business items are new drug research and development, biotechnology services, and research and development services, such as: commissioned research and development and production services for cell medicine, agency testing and development services, and biomedical consulting services, etc.
23GF Score

Get the complete analysis for ROCO:6986

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$47.00
Price